Literature DB >> 22677078

Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge.

Kachiu C Lee1, Barry Ladizinski, Daniel G Federman.   

Abstract

Levamisole is an immunomodulatory agent that was used to treat various cancers before being withdrawn from the United States market in 2000 because of adverse effects. Levamisole is currently approved as an antihelminthic agent in veterinary medicine, but is also being used illicitly as a cocaine adulterant. Potential complications associated with use of levamisole-laced cocaine include neutropenia, agranulocytosis, arthralgias, retiform purpura, and skin necrosis. Treatment is primarily supportive, and skin lesions typically resolve with cessation of cocaine use. The incidence of hospitalizations related to use of levamisole-contaminated cocaine continues to increase and clinicians should be aware of the more common clinical manifestations.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677078      PMCID: PMC3498128          DOI: 10.1016/j.mayocp.2012.03.010

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  38 in total

1.  Agranulocytosis in cocaine users in Ohio: suspected levamisole taint.

Authors:  Benjamin Herms; Michael Kaplon; Michael Baumann
Journal:  Leuk Res       Date:  2011-09       Impact factor: 3.156

2.  Prevalence of levamisole in urine toxicology screens positive for cocaine in an inner-city hospital.

Authors:  Jennie A Buchanan; Kennon Heard; Cynthia Burbach; Michael L Wilson; Richard Dart
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

3.  Levamisole-induced retiform purpura.

Authors:  James Click; Sarah Gee; Raul Cortes; Lydia Gedmintas; Joseph F Merola; Vivian Bykerk; Arturo Saveedra
Journal:  J Drugs Dermatol       Date:  2011-02       Impact factor: 2.114

4.  A boy with cutaneous necrosis occurring during treatment with levamisole.

Authors:  J Powell; H Grech; J Holder
Journal:  Clin Exp Dermatol       Date:  2002-01       Impact factor: 3.470

5.  Detection of levamisole exposure in cocaine users by liquid chromatography-tandem mass spectrometry.

Authors:  Kara L Lynch; Stephen S Dominy; Jonathan Graf; Alexander H Kral
Journal:  J Anal Toxicol       Date:  2011-04       Impact factor: 3.367

6.  Levamisole exposure and hematologic indices in cocaine users.

Authors:  Peter R Chai; William Bastan; Jason Machan; Jason B Hack; Kavita M Babu
Journal:  Acad Emerg Med       Date:  2011-11       Impact factor: 3.451

7.  Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome.

Authors:  Olivia Boyer; Janelle K Moulder; Laure Grandin; Michael J G Somers
Journal:  Pediatr Nephrol       Date:  2008-01-16       Impact factor: 3.714

8.  Chemotactic function of polymorphonuclear leukocytes from patients with recurrent infections: partial correction by levamisole "in vitro".

Authors:  A N Stein; R A Díez; L Sen; M E Estévez
Journal:  Allergol Immunopathol (Madr)       Date:  1985 Mar-Apr       Impact factor: 1.667

Review 9.  Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?

Authors:  J C Davin; M P Merkus
Journal:  Pediatr Nephrol       Date:  2004-09-17       Impact factor: 3.714

10.  Defective neutrophil motility and recurrent infection. In vitro and in vivo effects of levamisole.

Authors:  A R Rabson; R Anderson; A Glover
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

View more
  28 in total

1.  Purple ear and retiform purpura.

Authors:  Zaw Min; Alireza Zarrabi; Abera Woldesenbet; Richard B Williams
Journal:  Intern Emerg Med       Date:  2013-11-28       Impact factor: 3.397

2.  Levamisole toxicity.

Authors:  Robert W Graebner
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

3.  Cocaine-induced vasculitis: clinical and immunological spectrum.

Authors:  Luis R Espinoza; Rodolfo Perez Alamino
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

4.  Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole.

Authors:  B Choodamani; Karla G Cano Hernandez; Sujeet Kumar; Ann Maria Tony; Austre Y Schiaffino Bustamante; Renato J Aguilera; Dominique Schols; C Gopi Mohan; Subhas S Karki
Journal:  Chem Biodivers       Date:  2021-01-07       Impact factor: 2.408

5.  Retiform purpura caused by the use of cocaine, that was probably adulterated with levamisole.

Authors:  Jose Luis Torregrosa Calatayud; Juan Garcías Ladaria; Blanca De Unamuno Bustos; Violeta Zaragoza Ninet; Victor Alegre De Miquel
Journal:  Ann Dermatol       Date:  2015-02-03       Impact factor: 1.444

Review 6.  A Spotlight on Drug-Induced Vasculitis.

Authors:  Kinanah Yaseen; Alana Nevares; Hiromichi Tamaki
Journal:  Curr Rheumatol Rep       Date:  2022-09-21       Impact factor: 4.686

Review 7.  Stimulants and the lung : review of literature.

Authors:  Will Tseng; Mark E Sutter; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

8.  Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report.

Authors:  Lourdes Roca-Argente; Jose-Luis Moll-Guillen; Jordi Espí-Reig; Marino Blanes-Julia; Ana-María García-Martínez; Conrad Pujol-Marco; Julio Hernández-Jaras
Journal:  Ann Transl Med       Date:  2015-10

9.  Pulmonary hemorrhage in acute heroin overdose: a report of two cases.

Authors:  Gerald J Riccardello; Pierre D Maldjian
Journal:  Emerg Radiol       Date:  2017-07-04

10.  Biosurveillance of Drug Overdoses and Substance Misuse Treated in Selected Emergency Departments in Minnesota, 2017-2020.

Authors:  Terra Wiens; Elisabeth Bilden; Stefan Saravia; Jason Peterson; Matthew Wogen; Kaila Hanson; Roon Makhtal; Nate Wright; Jon Roesler; Ruth Lynfield
Journal:  Public Health Rep       Date:  2021 Nov-Dec       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.